Last reviewed · How we verify

NCT07503860

Indirect Biomarkers and Exercise Induced Muscle Damage

Active, enrolled NA Last updated 31 March 2026
What this trial tests

NA trial testing Eccentric Exercise in Exercise Induced Muscle Damage in 48 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
22 August 2025
Primary endpoint
27 November 2025
15 July 2026

Quick facts

Lead sponsorVassilis Paschalis
PhaseNA
StatusActive, enrolled
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposebasic science
Enrollment48
Start date22 August 2025
Primary completion27 November 2025
Estimated completion15 July 2026
Sites1 location across Greece

Drugs / interventions tested

Conditions studied

Sponsor

Vassilis Paschalis

Who can join

Adults 18 to 30, male only, with Exercise Induced Muscle Damage. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to investigate the magnitude of changes in biomarkers of exercise-induced muscle damage following an acute bout of eccentric exercise of the knee extensors performed on an isokinetic dynamometer. Moreover, these biomarkers will be assessed at different time points after the initial intervention, checking the repeated bout effect phenomenon.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Eccentric Exercise

Trials testing the same drug.

Other recruiting trials for Exercise Induced Muscle Damage

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07503860.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing